GEO series
Atractylenolide III Alleviates Cisplatin-Induced Acute Liver Injury by Regulating Gut-Liver Axis Through Inhibiting ACT1/TRAF6/NF-κB-Mediated IL-17 Pathway
GSE341526
Mus musculus
Expression profiling by high throughput sequencing
9 samples
2026/08/01
GPL30172
Summary
Introduction: Cisplatin (DDP) is a highly effective and broad-spectrum chemotherapeutic agent. However, its clinical application is limited by severe hepatotoxicity. Currently available hepatoprotective agents are often associated with insufficient efficacy or side effects. Therefore, developing new hepatoprotective agents that are highly efficient and low in toxicity is urgent. Objectives: Atractylodes macrocephala Koidz. is a well-known traditional Chinese medicine for strengthening the spleen function. According to the theory of traditional Chinese medicine, “When liver disease occurred, the spleen should be strengthened first” suggests that A. macrocephala Koidz. might possess hepatoprotective properties. Therefore, this study focuses on the molecular mechanism by which the active factors of A. macrocephala Koidz. exert their liver-protective effects. Methods: Animal experiments were adopted to screen the active factors of A. macrocephala Koidz. Multi-omics integrated analysis, including gut microbial diversity, transcriptomics, and metabolomics, combined with fecal microbiota transplantation (FMT) experiments were performed to clarify the mechanism of liver-protective effects of atractylenolide III (AT-III). Results: We found that AT-III-derived from A. macrocephala Koidz. significant decreased ALT, AST levels and hepatic pathological symptoms in DDP-induced acute liver injury (ALI). AT-III alleviated DDP-induced ALI via the “gut-liver axis” by inhibiting the ACT1/TRAF6/NF-κB-mediated IL-17 signaling pathway. Eight distinct microbial species, including Parabacteroides and Alloprevotella, were identified with significant differences. Besides, metabolite N6-(1,2-dicarboxyethyl)-AMP was identified as a novel biomarker for hepatotoxicity. Meanwhile, the FMT results indicated that the intestinal microbiota has a better alleviating effect on ALI than the metabolites of the intestinal microbiota.
Download
NCBI GEO page ↗
{# Names what the click gives you. "Open in finder" meant nothing to a
visitor who arrived from a search engine and has never seen the tool. #}
Find more
mouse RNA-seq datasets →
Similar datasets
- GSE292862 Modelling mouse embryogenesis from chemically induced totipotent stem cells 22 samples
- GSE185862 A taxonomy of transcriptomic cell types across the isocortex and hippocampal formation 95 samples
- GSE293315 MRPGRX2 Antagonist Treatment Prevents Inflammation and Disease in a Mouse Model of Atopic Dermatitis Dataset 2 35 samples
- GSE255837 Dysregulation of the Normal Wound Healing Cascade in Volumetric Muscle Loss Injury 30 samples
- GSE341948 Multi-tissue transcriptomic landscape reveals synergistic mechanisms of exercise and GLP-1 agonist in ameliorating diabetic phenotypes in db/db mice 12 samples
- GSE304862 Semaglutide and exercise synergy in obesity: preserving muscle mass and uncovering organ crosstalk 209 samples
- GSE337190 CAR-NKT cells induce low cytokine release syndrome by targeting hyperinflammatory macrophages with mitigation from GM-SCF inhibition. 24 samples
- GSE306116 Caspase-3 Control of RNA Splicing and Mitochondrial Dynamics in Microglia during Parkinson’s Disease [RNA-Seq] 12 samples
Share this dataset
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.